DOCSLIB.ORG

Reversible Bronchospasm with the Cardio-Selective Beta-Blocker Celiprolol in a Non-Asthmatic Subject

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reversible Bronchospasm with the Cardio-Selective Beta-Blocker Celiprolol in a Non-Asthmatic Subject Respiratory Medicine CME (2009) 2, 141e143 CASE REPORT Reversible bronchospasm with the cardio-selective beta-blocker celiprolol in a non-asthmatic subject Rubab Ahmed, Howard M. Branley* Department of Respiratory Medicine, The Whittington Hospital NHS Trust, Magdala Avenue, London N19 5NF, UK Received 5 October 2008; accepted 16 October 2008 KEYWORDS Summary Selective beta blockers; Beta (b)-blockers are widely used in the treatment of cardiovascular disease but are well Celiprolol; recognised for causing bronchoconstriction in asthmatic subjects. The third-generation car- Bronchoconstriction; dio-selective b-blocker celiprolol is a selective b1-adrenergic blocking agent with b2-agonist Asthma properties and would therefore be a preferred b-blocker if an asthmatic subject required treat- ment with b-blockers for cardiovascular disease. We present the case of a 79-year-old man with ischaemic heart disease and hypertension but no preceding respiratory disease who developed significant bronchoconstriction on celiprolol, which resolved completely on drug cessation alone with no relapse of respiratory symptoms two years after cessation of treatment. ª 2008 Published by Elsevier Ltd. Introduction relatively cardio-selective but are not cardio-specific. Cel- iprolol additionally possesses vasodilator properties b-blockers are widely used in the treatment of cardiovas- through blockade of vascular alpha-adrenoceptors. Celiprolol has been widely reported as being non-bron- cular disease, including hypertension, angina, myocardial 1,2 b choconstrictive both in subjects with asthma and infarction, arrhythmias and heart failure. -blockers bind 3,4 to b-adrenoceptors, thereby blocking the effects of propranolol-induced bronchoconstriction. epinephrine and norepinephrine. Some b-blockers, not only We report a case of significant bronchospasm in a patient prevent binding of sympathoamines to the b-adrenoceptor taking celiprolol with no previous history of airway disease, but also partially activate the b-adrenoceptor, and are thus which resolved completely on cessation of the drug. said to possess intrinsic sympathomimetic activity (ISA). Early b-blockers are non-selective, in that they block Case report both b-1 (cardiac) and b-2 (bronchial) adrenoceptors and can lead to unwanted b-2-blockade effects such as airflow A 79-year-old man presented with a 3-year history of obstruction. Newer b-blockers such as celiprolol are wheeze, especially at night. There was no dyspnoea or * Corresponding author. Tel.: þ44 20 7288 5353; fax: þ44 20 7288 5060. E-mail address: [email protected] (H.M. Branley). 1755-0017/$34 ª 2008 Published by Elsevier Ltd. doi:10.1016/j.rmedc.2008.10.019 142 R. Ahmed, H.M. Branley Figure 1 (a) PEFR diary on celiprolol demonstrating significant (35%) diurnal PEFR variation; (b) PEFR diary off celiprolol demonstrating non-significant (9%) diurnal PEFR variation. cough. He gave up smoking 30 years ago after 15 pack Discussion years’ consumption. He had ischaemic heart disease and hypertension, for which he took celiprolol 200 mg twice b-blocker induced bronchoconstriction in asthma is widely daily and had been for the preceding 10 years. There was reported, even with the cardio-selective b-blocker ateno- no history of atopic disease, no family history of asthma and lol.5e7 However, b-blocker induced bronchoconstriction in he had no occupational exposures. non-asthmatic subjects is exceedingly rarely reported and Physical examination revealed a clear chest with normal then, only with non-cardio-selective agents such as breath sounds and no added sounds. Peak expiratory flow propranolol.8,9 To the best of our knowledge there are no rate (PEFR) 274 L/min. Spirometry did not demonstrate reported cases of celiprolol-induced bronchoconstriction in airflow obstruction with forced expiratory volume in 1 s non-asthmatic subjects. In fact, celiprolol has been (FEV1) 2.04 L, forced vital capacity (FVC) 2.24 L (ratio 91%). widely reported as being non-bronchoconstrictive both Chest X-ray revealed a cardiothoracic ratio of 18/29 cm in subjects with asthma1,2 and propranolol-induced with clear lung fields. bronchoconstriction.3,4 A PEFR diary [Fig. 1(a)], whilst continuing celiprolol, What makes this case even more interesting is that showed a peak of 460 L/min and trough of 300 L/min celiprolol is regarded as providing a greater margin of (diurnal variation 35%). Following this observation, cel- respiratory safety than other cardio-selective b-blockers7 iprolol was stopped and a repeat PEFR diary [Fig. 1(b)] was due to its b2 agonist and intrinsic sympathomimetic activity recorded after cessation of celiprolol for 3 months. This (ISA). showed a peak of 460 L/min and trough of 420 L/min Celiprolol is a third-generation b-adrenoceptor blocker (diurnal variation 9%). Coincident with this improvement in with selective b-1-antagonist, partial b-2-agonist and mild PEFR was complete resolution of all respiratory symptoms. alpha-2-antagonist actions, with less risk of vasoconstric- During a 2-year period of follow-up there was no recurrence tion, bronchoconstriction and myocardial depression due to of any respiratory symptoms. Celiprolol-induced bronchospasm 143 its ISA. Whilst not being previously described as causing The onset of adverse effects from b-blockers is not bronchoconstriction, celiprolol is reported to cause hyper- necessarily temporally related to the initiation of sensitivity pneumonitis with a lymphocytic alveolitis, which treatment. resolves completely on celiprolol cessation.10 When celiprolol is directly compared to another cardio- selective b-blocker (atenolol) in asthmatic subjects, it has Conflict of interest statement been shown that atenolol is associated with bronchocon- striction but that there is no difference in day-to-day Neither author has any conflict of interest in relation to any asthma control, as judged by PEFR diary, inhaler use and aspect of this manuscript. symptom scores.7 Our patient fulfilled the criteria for diagnosing asthma Funding according to the British Thoracic Society/Scottish Inter- collegiate Guidelines Network (BTS/SIGN) British guide- None. line on the management of asthma 2008. There was significant diurnal variation in PEFR clearly demonstrated References whilst taking celiprolol, which completely resolved on cessation of the drug. Follow-up for 2 years of celiprolol failed to demonstrate any recurrence of respiratory 1. Bruschi C, Casali L, Cerveri I, Peona V, Zoia MC. Effects of celiprolol on the bronchial reactivity in asthma. Am J Cardiol symptoms. 1988;61(5):53Ce4. One common feature of most published data involving 2. Dorow P. Celiprolol e review of airways studies. Am J Cardiol b-blocker usage in asthma is the relatively small number of 1988;61(5):23Ce6. patients recruited in each study, emphasising the need for 3. Matthys H, Doshan HD, Ruhle KH, Braig H, Pohl M, Applin WJ, et al. a larger scale study in this area. The bronchosparing effect of celiprolol, a new beta 1- alpha 2-receptor antagonist on pulmonary function of propranolol- e Conclusions sensitive asthmatics. J Clin Pharmacol 1985;25(5):354 9. 4. Pujet JC, Dubreuil C, Fleury B, Provendier O, Abella ML. Effects of celiprolol, a cardioselective beta-blocker, on respiratory We present the first case of celiprolol-induced broncho- function in asthmatic patients. Eur Respir J 1992;5(2):196e200. spasm in a non-asthmatic subject, which resolved 5. Doshan HD, Brown R, Applin WJ, Kapoor M, Caruso FS. Effects completely on celiprolol cessation alone. Although cel- of high doses of celiprolol in asthmatic patients. J Cardiovasc iprolol is cardio-selective we would still urge caution and Pharmacol 1986;8(Suppl. 4):S109e11. close observation for the development of respiratory 6. Schindl R, Wurtz J, Hoffmann H. The effect of the cardioselective adverse effects when initiating cardio-selective beta blocker celiprolol on pulmonary function in asthmatic e b-blockers, even in patients without a preceding history of patients. J Cardiovasc Pharmacol 1986;8(Suppl. 4):S99 101. 7. van Zyl AI, Jennings AA, Bateman ED, Opie LH. Comparison of Asthma. respiratory effects of two cardioselective beta-blockers, cel- We would also like to emphasise that the development iprolol and atenolol, in asthmatics with mild to moderate of respiratory symptoms can be delayed, and hence the hypertension. Chest 1989;95(1):209e13. need to consider drugs in new onset respiratory 8. Clark BG, Araki M, Rawlings JL. Propranolol-induced dyspnea in symptoms. a nonasthmatic male. Drug Intell Clin Pharm 1982;16(10):776e7. 9. Ryo UY, Townley RG. Comparison of respiratory and cardio- Learning points vascular effects of isoproterenol, propranolol, and practolol in asthmatic and normal subjects. J Allergy Clin Immunol 1976; 57(1):12e24. b-blocker induced bronchospasm can develop in non- 10. Lombard JN, Bonnotte B, Maynadie M, Foucher P, Reybet asthmatic patients even with cardio-selective agents Degat O, Jeannin L, et al. Celiprolol pneumonitis. Eur Respir such as celiprolol. J 1993;6(4):588e91..
Load more

Recommended publications
  • Differentiating Between Anxiety, Syncope & Anaphylaxis
    Differentiating between anxiety, syncope & anaphylaxis Dr. Réka Gustafson Medical Health Officer Vancouver Coastal Health Introduction Anaphylaxis is a rare but much feared side-effect of vaccination. Most vaccine providers will never see a case of true anaphylaxis due to vaccination, but need to be prepared to diagnose and respond to this medical emergency. Since anaphylaxis is so rare, most of us rely on guidelines to assist us in assessment and response. Due to the highly variable presentation, and absence of clinical trials, guidelines are by necessity often vague and very conservative. Guidelines are no substitute for good clinical judgment. Anaphylaxis Guidelines • “Anaphylaxis is a potentially life-threatening IgE mediated allergic reaction” – How many people die or have died from anaphylaxis after immunization? Can we predict who is likely to die from anaphylaxis? • “Anaphylaxis is one of the rarer events reported in the post-marketing surveillance” – How rare? Will I or my colleagues ever see a case? • “Changes develop over several minutes” – What is “several”? 1, 2, 10, 20 minutes? • “Even when there are mild symptoms initially, there is a potential for progression to a severe and even irreversible outcome” – Do I park my clinical judgment at the door? What do I look for in my clinical assessment? • “Fatalities during anaphylaxis usually result from delayed administration of epinephrine and from severe cardiac and respiratory complications. “ – What is delayed? How much time do I have? What is anaphylaxis? •an acute, potentially
    [Show full text]
  • (Loxapine) REMS
    Current as of 6/1/2013.® This document may not be part of the latest approved REMS. Alexza Pharmaceuticals, Inc. 2091 Stierlin Court, Mountain View, CA 94043 IMPORTANT DRUG WARNING Risk of bronchospasm with ADASUVE™ (loxapine) inhalation powder ADASUVE™ available only in enrolled healthcare facilities, under an FDA-required REMS Program Dear Healthcare Professional: This letter contains important safety information for ADASUVE™ (loxapine) Inhalation Powder. ADASUVE is a drug-device combination product that delivers the antipsychotic, loxapine, by oral inhalation. ADASUVE has been approved by the US Food and Drug Administration (FDA) for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of treatment outweigh the risk of bronchospasm in patients treated with ADASUVE. ADASUVE is not available in an outpatient setting. If you are an outpatient provider, you are receiving this letter because ADASUVE may be, or may have been, administered to one of your patients in an enrolled healthcare facility. Enrolled healthcare facilities, such as an acute care or inpatient setting, must have immediate on-site access to equipment and personnel trained to manage acute bronchospasm, including advanced airway management, eg, intubation and mechanical ventilation. (See below for more facility enrollment requirements.) It is important that anyone caring for patients treated with ADASUVE be aware of the risk of bronchospasm after administration. This letter does not contain a complete list of all the risks associated with ADASUVE. Reference ID:Please 3235446 see the enclosed full prescribing information for more information.
    [Show full text]
  • Inhaled Loxapine Monograph
    Inhaled Loxapine Monograph Inhaled Loxapine (ADASUVE) National Drug Monograph February 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Inhaled loxapine is a typical antipsychotic used in the treatment of acute Action agitation associated with schizophrenia and bipolar I disorder in adults. Loxapine’s mechanism of action for reducing agitation in schizophrenia and bipolar I disorder is unknown. Its effects are thought to be mediated through blocking postsynaptic dopamine D2 receptors as well as some activity at the serotonin 5-HT2A receptors. Indication(s) Under Review in Inhaled loxapine is a typical antipsychotic indicated for the acute treatment of this document (may include agitation associated with schizophrenia or bipolar I disorder in adults. off label) Off-label use Agitation related to any other cause not due to schizophrenia and bipolar I disorder. Dosage Form(s) Under 10mg oral inhalation using a new STACCATO inhaler device. Review REMS REMS No REMS Post-marketing Study Required See Other Considerations for additional REMS information Pregnancy Rating C Executive Summary Efficacy Inhaled loxapine was superior to placebo in reducing acute agitation at 2 hours post dose measured by the Positive and Negative Syndrome Scale-Excited Component (PEC) in patients with bipolar I disorder and schizophrenia.
    [Show full text]
  • Beta Adrenergic Agents
    Beta2 Adrenergic Agents –Long Acting Review 04/10/2008 Copyright © 2007 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Comments and suggestions may be sent to [email protected].
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • BREATHLESSNESS ABSTRACT INTRODUCTION Dyspnoea, Also
    EMERGENCY MEDICINE – WHAT THE FAMILY PHYSICIAN CAN TREAT UNIT NO. 4 BREATHLESSNESS In one study of 85 patients presenting to a pulmonary unit Psychiatric conditions appropriate context of the history, physical examination, and ischaemia. Serial measurements of cardiac biomarkers are inhaler (MDI). In severe asthma, patients should be transferred breathlessness. In such cases, it is prudent to start therapies for with a complaint of chronic dyspnoea, the initial impression Psychogenic causes for acute dyspnoea is a diagnosis of the consideration of dierential diagnosis. Random testing necessary as initial results can often be normal. to ED for further treatment with nebulised ipratropium multiple conditions in the initial resuscitative phase. For Dr Pothiawala Sohil of the aetiology of dyspnoea based upon the patient history exclusion, and organic causes must be ruled out rst before without a clear dierential diagnosis will delay appropriate bromide, intravenous magnesium, ketamine, IM adrenaline, example, for a patient with a past medical history of COPD and alone was correct in only 66 percent of cases.4 us, a considering this diagnosis (e.g., panic attack).5 management. e use of dyspnoea biomarker panels does not Brain natriuretic peptide (BNP) intubation, and inhalational anaesthesia as needed. congestive cardiac failure, the initial management of sudden systematic approach, comprising of adequate history and appear to improve accuracy beyond clinical assessment and is is used to diagnose heart failure, but it can also be elevated onset of dyspnoea may include therapies directed at both these ABSTRACT diagnostic studies, and provide recommendations for initial physical examination, followed by appropriate investigations focused testing.6, 7 in uid overload secondary to renal failure.
    [Show full text]
  • Interactions with HBV Treatment
    www.hep-druginteractions.org Interactions with HBV Treatment Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 1 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF. ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Anaesthetics & Muscle Relaxants Antibacterials (continued) Bupivacaine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisatracurium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapsone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoflurane ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Delamanid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ketamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ertapenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nitrous oxide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Erythromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Propofol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethambutol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiopental ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flucloxacillin ◆ ◆ ◆ ◆ ◆ ◆ Tizanidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gentamicin ◆ ◆ ◆ ◆ ◆ ◆ Analgesics Imipenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aceclofenac ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoniazid ◆ ◆ ◆ ◆ ◆ ◆ Alfentanil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aspirin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Linezolid ◆ ◆ ◆ ◆ ◆ ◆ Buprenorphine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lymecycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Celecoxib ◆ ◆ ◆ ◆ ◆ ◆ ◆ Meropenem ◆ ◆ ◆ ◆ ◆ ◆ Codeine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for Methenamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dexketoprofen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Metronidazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dextropropoxyphene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moxifloxacin ◆ ◆ ◆
    [Show full text]
  • Adasuve, INN-Loxapine
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT ADASUVE 4.5 mg inhalation powder, pre-dispensed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each single-dose inhaler contains 5 mg loxapine and delivers 4.5 mg loxapine. 3. PHARMACEUTICAL FORM Inhalation powder, pre-dispensed (inhalation powder). White device with a mouthpiece on one end and a pull-tab protruding from the other end. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications ADASUVE is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. 4.2 Posology and method of administration ADASUVE should only be administered in a hospital-setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects (bronchospasm). Posology The recommended initial dose of ADASUVE is 9.1 mg. A second dose can be given after 2 hours, if necessary. No more than two doses should be administered. A lower dose of 4.5 mg may be given if the 9.1 mg dose was not previously tolerated by the patient or if the physician decides a lower dose is more appropriate. Patient should be observed during the first hour after each dose for signs and symptoms of bronchospasm. Elderly The safety and efficacy of ADASUVE in patients older than 65 years of age have not been established. No data are available. Renal and/or hepatic impairment ADASUVE has not been studied in patients with renal or hepatic impairment.
    [Show full text]
  • Antihypertensive?
    Which Antihypertensive? www.bpac.org.nz keyword: antihypertensive 14 | BPJ | Issue 31 Choosing an antihypertensive medicine There is much debate on which antihypertensive medicine is the most appropriate first choice. In practice, combination treatment is ultimately needed to control blood pressure The main benefit of any antihypertensive treatment is in the majority of patients so it is less important which lowering of blood pressure and this is largely independent antihypertensive is used initially.2 Some patients may of the class of medicine used.1 Once the decision has respond well to one medicine but not to another.1 been made to initiate antihypertensive treatment, choice of medicine should be based on individual patient Beta blockers are not usually considered for first line characteristics including age and co-morbidities. treatment of hypertension, except when used for their protective effect in ischaemic heart disease and heart The main classes of antihypertensive medicines are; failure, and for their rate-controlling effect in atrial thiazide diuretics, angiotensin converting enzyme (ACE) fibrillation.3 The effectiveness of beta blockers in inhibitors (or angiotensin receptor blocker [ARB] for those reducing major cardiovascular events (stroke in particular) who are not able to tolerate an ACE inhibitor),calcium compared to other antihypertensive agents is currently channel blockers and beta blockers. under review. Key concepts ■ In patients with uncomplicated, mild combination therapy - the majority of people hypertension
    [Show full text]
  • Celiprolol Pneumonitis
    Copyright ~ERS Journala Ltd 1993 Eur Resplr J, 1993, 8, 588-591 European Respiratory Journal Printed In UK • all rlghta reserved ISSN 0903 • 1938 CASE REPORT Celiprolol pneumonitis J.N. Lombard*, B. Bonnotte*, M. Maynadie**, P. Foucher*, 0. Reybet Degat*, L. Jeannin*, Ph. Camus* Celiprolol pneumonitis. J.N. Lombard, B. Bonnotte, M. Maynadie, P. Foucher, 0. Reybet • Service de Pneumologie et de R6an­ Degat, L. Jeannin, Ph. Camus. @ERS Journals Ltd 1993. imation Respiratoire, Centre Hospitalier ABSTRAcr: We report on a patient who developed bypersensitlvity pneumonitis Universitaire et Universit6 de Bourgogne, during treatment with the ~-blocker, cellprolol. The clinical picture was a severe Dijon, France. •• Laboratoire d'H6mato· logic, Dijon, France. alveolltis, with compromised gas exchange. Inadvertent subsequent rechalleoge with cellprolol led to recurrence of the pneumonitis, 10 wee.ks after drug readmlnlstration. Correspondence: Ph. Camus, Service de Again, the pneumonitis was fully reversible. Lymphocytes were elevated In Pneumologie et de R6animation Respira­ broncboalveolar lavage, and progressively nonnallzed upon discontinuation of the toire, Centre Hospitalier Universitaire et Universit~ de Bourgogne, 21034 Dijon, drug. This case Is reminiscent of pneumonitis to other ~-blockers, which are France reviewed here. Keywords: Beta-blockers; celiprolol; hy­ Eur Respir J., 1993, 6, 588-591. persensitivity pneumonitis; interstitial lung disease (drug-induced) Received: November 9 1992 Accepted for publication January 31 1993 1 Beta-blockers can induce several types of adverse res­ (normal (N) <40 IU·/" ), alanine amino transferase 47 piratory reactions such as life-threatening asthma attacks, IU·l·1 (N <21 IU·l-1), gamma glutamyl transpeptidase 1 reversible interstitial pneumonitis, an oculo-mucocutane­ 116 IU·l·1 (N <28 IU·l- ), and alkaline phosphatase 102 ous syndrome, and pleural effusions with or without the IU·/"1 (N <63 IU·z-t).
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use SPIRIVA HANDIHALER Safely and Effectively
    SPIRIVA HANDIHALER- tiotropium bromide capsule A-S Medication Solutions ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA HANDIHALER safely and effectively. See full prescribing information for SPIRIVA HANDIHALER. SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder), for oral inhalation use Initial U.S. Approval: 2004 INDICATIONS AND USAGE SPIRIVA HANDIHALER is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations (1) DOSAGE AND ADMINISTRATION For oral inhalation only. DO NOT swallow SPIRIVA capsules. Only use SPIRIVA capsules with the HANDIHALER device (2) Two inhalations of the powder contents of a single SPIRIVA capsule (18 mcg) once daily (2) DOSAGE FORMS AND STRENGTHS Inhalation powder: SPIRIVA capsules contain 18 mcg tiotropium powder for use with HANDIHALER device (3) CONTRAINDICATIONS Hypersensitivity to tiotropium, ipratropium, or any components of SPIRIVA capsules (4) WARNINGS AND PRECAUTIONS Not for acute use: Not a rescue medication (5.1) Immediate hypersensitivity reactions: Discontinue SPIRIVA HANDIHALER at once and consider alternatives if immediate hypersensitivity reactions, including angioedema, urticaria, rash, bronchospasm, or anaphylaxis, occur. Use with caution in patients with severe hypersensitivity to milk proteins. (5.2) Paradoxical bronchospasm: Discontinue SPIRIVA HANDIHALER and consider other treatments if paradoxical bronchospasm occurs (5.3) Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to consult a physician immediately if this occurs. (5.4) Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to consult a physician immediately if this occurs.
    [Show full text]
  • Ipratropium Bromide Solution Cobalt Laboratories, Inc.
    IPRATROPIUM BROMIDE- ipratropium bromide solution Cobalt Laboratories, Inc. ---------- Prescribing Information Rx Only DESCRIPTION The active ingredient in Ipratropium Bromide Inhalation Solution is ipratropium bromide monohydrate. It is an anticholinergic bronchodilator chemically described as 8-azoniabicyolo[3.2.1]-octane, 3-(3- hydroxy-1-oxo-2-phenyl-propoxy)-8 methyl-8-(1-methylethyl)-, bromide, monohydrate (endo, syn)-,(±)- ; a synthetic quaternary ammonium compound, chemically related to atropine. Ipratropium bromide is a white crystalline substance, freely soluble in water and lower alcohols. It is a quaternary ammonium compound and thus exists in an ionized state in aqueous solutions. It is relatively insoluble in non-polar media. Ipratropium Bromide Inhalation Solution is administered by oral inhalation with the aid of a nebulizer. It contains ipratropium bromide 0.02% (anhydrous basis) in a sterile, isotonic saline solution, pH-adjusted to 3.4 (3 to 4) with hydrochloric acid. CLINICAL PHARMACOLOGY Ipratropium bromide is an anticholinergic (parasympatholytic) agent that, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increases in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) that are caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. The bronchodilation following inhalation of ipratropium bromide is primarily a local, site-specific effect, not a systemic one. Much of an administered dose is swallowed but not absorbed, as shown by fecal excretion studies. Following nebulization of a 2 mg dose, a mean 7% of the dose was absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract.
    [Show full text]